Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature

Table 2 Tyrosine kinase inhibitors for treatments of thyroid cancer

Medication	Target	Indication	Ref.
Vandetanib	RET-tyrosine kinase, VEGFR and EGFR	Unresectable locally advanced or metastatic thyroid cancer	[24]
Cabozantinib	c-Met- tyrosine kinase, VEGFR 2, RET-tyrosine kinase, AXL	RAIR locally advanced or metastatic thyroid cancer after VEGFR-targeted therapy	[25]
Sorafenib	VEGFR 1-3, PDGFR and RAF and RET-kinases	Metastatic RAIR thyroid cancer	[26]
Lenvatinib	VEGFRs 1-3, FGFRs 1- 4, PDGFR-α, RET and KIT signaling	RAIR thyroid cancer	[27]

AXL: Tyrosine-protein kinase receptor UFO; FGFR: Fibroblast growth factor receptor; PDGFR: Platelet-derived growth factor receptor; RAIR: Radioactive iodine-refractory; VEGFR: Vascular endothelial growth factor receptor.